Method for Treating Phytophotodermatitis
US-2016030381-A1 · Feb 4, 2016 · US
US10287246B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10287246-B2 |
| Application number | US-201815890578-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 7, 2018 |
| Priority date | Jan 3, 2011 |
| Publication date | May 14, 2019 |
| Grant date | May 14, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to methods, formulations, and compositions for the treatment of biofilms. In particular, the application discloses isothiocyanate functional surfactants either alone or combination with adjunct agents to treat biofilms. One suitable isothiocyanate functional surfactant is represented by the following chemical structure:
Opening claim text (preview).
What is claimed and desired to be secured by Letters Patent of the United States is: 1. A method, comprising the step of administering to a patient having a biofilm a composition comprising an isothiocyanate functional surfactant, wherein the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure: 2. The method according to claim 1 , wherein the composition comprising the isothiocyanate functional surfactant is administered to the patient at least one of orally, intravenously, intramuscularly, intrathecally, cutaneously, subcutaneously, transdermally, sublingually, buccally, rectally, vaginally, ocularly, otically, and nasally. 3. The method according to claim 1 , wherein the composition comprising the isothiocyanate functional surfactant is topically administered to the patient. 4. The method according to claim 3 , wherein the amount of isothiocyanate functional surfactant in the composition topically administered to the patient ranges from approximately 0.5 nmol/cm2 to approximately 10 μmol/cm2. 5. The method according to claim 4 , wherein the composition comprising the isothiocyanate functional surfactant is a topical preparation selected from the group consisting of ointment, cream, emulsion, lotion and gel. 6. The method according to claim 5 , wherein the composition further comprises one or more pharmaceutical, biological or molecular biological active agents. 7. The method according to claim 6 , wherein the patient is a mammal. 8. The method according to claim 7 , wherein the mammal is a human.
Antibacterial agents · CPC title
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) · CPC title
Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.